Japanese Encephalitis Vaccine Market

Japanese Encephalitis Vaccine Market

Japanese encephalitis (JE) is a contamination of the mind brought about by the Japanese encephalitis infection (JEV). While most contaminations bring about almost no manifestations, incidental aggravation of the cerebrum happens. In these cases, indications may incorporate migraine, retching, fever, disarray and seizures. This happens around 5 to 15 days after contamination.

JE vaccine is prescribed for people moving to a JE-endemic nation to live, longer-term (e.g., multi month or more) voyagers, and successive explorers to JE-endemic regions. JE vaccine likewise ought to be considered for more limited term (e.g., under multi month) explorers with an expanded danger of JE dependent on arranged travel span, season, area, exercises, and facilities. Immunization likewise ought to be considered for explorers to endemic regions who are unsure of explicit term of movement, objections, or exercises.

JE vaccine isn't suggested for explorers with generally safe agendas, for example, more limited term venture out restricted to metropolitan regions or travel that happens outside of a clear cut JE infection transmission season. The growing awareness about the infection, expansion in movement and the travel industry, government drive to destroy the illness, pig cultivating, section of new vaccine producers, created R and D and so on, expanding mosquito disturbance are some driving factors for the development of the worldwide Japanese encephalitis market in the years to come.

Japanese encephalitis (JE) is inflammation of brain which is caused by Japanese encephalitis virus (JEV). This virus belongs to family Flaviviradae.  JEV is considered as the most important cause of encephalitis in Asia. JEV is mosquito born flavivirus, belonging to same genus as dengue. It is spread by mosquitoes of Culex sp. Pig and birds are reservoirs of the virus and help in spreading and maintaining the JEV cycle. The disease caused by the virus has no cure. Effective vaccines are available which can prevent JE. JE vaccine is recommended to be integrated into national immunization schedule where JE disease is a public concern.

The global Japanese encephalitis vaccine market is estimated to grow at a significant rate over the forecast period. According to WHO, the estimated annual number of clinical cases of JE are about 68000 globally. Thus rise in prevalence and incidence of the disease is one of the most important factor expected to drive the growth of global Japanese encephalitis vaccine market during the forecast period. Furthermore, rise in awareness about the disease, increase in travel and tourism, government initiative to eradicate the disease, pig farming, entry of new vaccine manufacturers, developed R & D etc, increasing mosquito nuisance are few other factors fuelling the growth of the global Japanese encephalitis market through 2025. Factors such as stringent government regulation regarding efficacy and safety, lack of awareness lack of supply of the vaccine in remote areas can be the major restraining factors for global Japanese encephalitis vaccine market during the forecast period.

The global Japanese encephalitis vaccine market can be segmented into product type, distribution channel and regions. On the basis of product type, the global Japanese encephalitis vaccine market can be divided into mouse brain derived vaccine, live attenuated vaccine, live recombinant vaccine, inactivated Vero-cell derived vaccine. Vero cell derived vaccine segment is expected to account for a significant share of the market during the forecast period since mouse brain derived vaccine  are being replaced cell based vaccine, due to higher efficacy and safety and animal ethical regulations. Based on the distribution channel the global JE vaccine market can be divided into hospital pharmacies, retail pharmacies and E-commerce.

Geographically the global Japanese encephalitis vaccine market is divided into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America is anticipated to dominate the human rabies vaccine market with the largest share during the forecast period. Surge in investment from government and public sector, programs to eradicate JE and yellow fever from the region etc are few factors propelling the growth of the global market in the North America. Furthermore, rise in awareness, robust research activities on yellow fever and JEV, high health care expenditure etc. are some other factors leading to market growth in the region. Asia Pacific market is anticipated to register a faster growth rate during the forecast period. The Asia Pacific is the most lucrative market due to high prevalence of the JE, government induced immunization programs, growing investment in R & D sector, entry of new vaccine manufacturers in the countries like India and China, increase number of travelers in the region, medical tourism etc.  Furthermore, increase in pig farms, poultry and mosquito nuisance in the region etc, are some of the factors anticipated to drive the growth of market in the region.

Some of the prominent players operating in the global Japanese encephalitis vaccine market are Valneva SE, Bharat Biotech, Sanofi Pasteur SA, Biological E Chengdu Institute of Biological Products Co, Ltd and others.